Esperion Therapeutics, Inc.’s ESPR share price has surged by 9.71%, which has investors questioning if this is right time to ...

Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ...

Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors ...

A live webcast of the event will also be available. These candidates are novel allosteric inhibitors of ATP citrate lyase (ACLY), a key metabolic enzyme with emerging relevance in hepatic ...

Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across ...

Nexletol (bempedoic acid) was approved as an alternative to statins in 2020 as the first drug in the ATP Citrate Lyase (ACL) inhibitor class, and was once tipped as a future blockbuster ...

A live webcast of the event will also be available. These candidates are novel allosteric inhibitors of ATP citrate lyase (ACLY), a key metabolic enzyme with emerging relevance in hepatic ...

The live webcast can be accessed on the investor and media section of the Esperion website . Access to the webcast replay will be available approximately two hours after the completion of the call and ...